- Home
- PODC vs MRSN Comparison
PODC vs MRSN Comparison
Compare PODC & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- MRSN
- Stock Information
- Founded
- PODC 2013
- MRSN 2001
- Country
- PODC United States
- MRSN United States
- Employees
- PODC N/A
- MRSN N/A
- Industry
- PODC
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- MRSN Health Care
- Exchange
- PODC Nasdaq
- MRSN Nasdaq
- Market Cap
- PODC 42.8M
- MRSN 37.0M
- IPO Year
- PODC N/A
- MRSN 2017
- Fundamental
- Price
- PODC $1.50
- MRSN $7.16
- Analyst Decision
- PODC
- MRSN Strong Buy
- Analyst Count
- PODC 0
- MRSN 4
- Target Price
- PODC N/A
- MRSN $63.67
- AVG Volume (30 Days)
- PODC 62.2K
- MRSN 137.0K
- Earning Date
- PODC 08-13-2025
- MRSN 08-13-2025
- Dividend Yield
- PODC N/A
- MRSN N/A
- EPS Growth
- PODC N/A
- MRSN N/A
- EPS
- PODC N/A
- MRSN N/A
- Revenue
- PODC $53,954,000.00
- MRSN $34,769,000.00
- Revenue This Year
- PODC $17.91
- MRSN N/A
- Revenue Next Year
- PODC $14.41
- MRSN $1.03
- P/E Ratio
- PODC N/A
- MRSN N/A
- Revenue Growth
- PODC 17.74
- MRSN 16.14
- 52 Week Low
- PODC $1.10
- MRSN $5.21
- 52 Week High
- PODC $2.94
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- PODC 36.51
- MRSN 48.25
- Support Level
- PODC $1.50
- MRSN $5.21
- Resistance Level
- PODC $1.69
- MRSN $7.72
- Average True Range (ATR)
- PODC 0.16
- MRSN 0.53
- MACD
- PODC 0.00
- MRSN 0.07
- Stochastic Oscillator
- PODC 8.16
- MRSN 77.84
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.